Clinical Trial Detail

NCT ID NCT00574587
Title Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Montefiore Medical Center
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel + Vorinostat

Trastuzumab

Cyclophosphamide + Doxorubicin

Age Groups: adult

Additional content available in CKB BOOST